



ASX ANNOUNCEMENT

13 OCTOBER 2026

Q1 FY2027 Operational Update

Encouraging First Quarter With Focus on Return to Profitability

Melbourne, Australia – Vitura Health Limited (ASX: VIT) (**Vitura and Company**), a leading digital health business, has delivered a strong start to FY2027, with first-quarter performance ahead of expectations across revenue, EBITDA and operating expenditure.

Q1 FY2027 Key Highlights*:

- **Revenue:** Up \$1.7 million, or 4.8% vs PCP;
- **EBITDA:** Up \$1.01 million, or 197.5% vs PCP; and
- **Operational Expenditure:** Down \$685,000, or -9.5% vs PCP.

Vitura has entered FY2027 with a clear focus on disciplined execution, strengthening its operations and returning the business to profitability. The Company has finalised its Three Horizon Plan, which has been endorsed by the Board and sets out a phased approach to delivering sustainable growth over the short, medium and long term. Work is now underway on Horizon One, a 12–18 month clear focus on:

- Improving patient access through stronger distribution and fulfilment capabilities;
- Enhancing the Group's platforms, systems and processes;
- Embedding a consistent clinical governance framework;
- A comprehensive review of contracting and margin stability; and
- Rigorous expense discipline.

These initiatives are designed to strengthen the core business and build a scalable foundation for future growth. The Company looks forward to sharing more details on its Three Horizon Plan at the upcoming Annual General Meeting on 27 November 2026.

Candor and Canview

The Company's positive start to Q1 FY2027 was supported by growth across both Candor's B2C clinical services and Canview's B2B ordering and prescribing platform. Candor's overall patient consultations increased during the period, with growth in check-up consultations. Medical cannabis dispensing volumes in the quarter were up by 19% compared to Q4, FY2026, contributing to revenue growth, with margins on these sales also continuing to improve.

The Company saw improved performance through Canview's promotional program for pharmacies during Q1 FY2027 which delivered strong sales growth.

Doctors on Demand

Doctors on Demand revenue exceeded expectations in Q1 FY2027, with increased consultation numbers driven by continued Bupa consultations. Underlying consultation volumes, excluding Bupa International patients, also remained above expectations for the quarter. The Bupa International Student transition is complete, with the International Visitor transition having commenced on 9 September 2026.

With Bupa patient consults winding down, focus is now on aligning Doctors on Demand's operating infrastructure to anticipated volumes and growing strategic B2B and B2C pipelines.

Emerging Markets

Nicotine Vaping Product revenue experienced strong growth (Up 107% in Q1 FY2027 vs PCP) with forecasts set to exceed FY2027 expectations, while Cortexa continues to support Emyria's expansion into Sydney with product supply.

The addition of Curaleaf to Vitura's supplier network further broadened the Company's supplier network and product offering during the quarter. This provides the Company with diversification in revenue and fuels the Company's growth in new emerging markets.

Vitura's Chief Executive Officer, Justin James, said:

"Vitura has made an encouraging start to FY2027 across our key areas of medical cannabis (Candor and Canview), 24/7 GP telehealth (Doctors on Demand) and emerging market opportunities such as MDMA supply (Cortexa) and Nicotine Vaping Products.

"Our priorities are clear with execution and profitability being front and centre. The Company's strategic plan addressing our core business, emerging growth opportunities and future thinking is also now being rolled out across the organisation.

"While we're pleased with our early results in FY2027, there is an absolute awareness that industry pressures and continued recovery work will require a tenacious and disciplined effort. We remain focussed on continuing to deliver a profitable and patient-focused healthcare business which positively changes the health of every patient we interact with."

ENDS

*** Revenue, EBITDA and OPEX numbers are unaudited at this stage.**

Authorised by - The Board of Vitura Health Limited

Contact:**Vitura Health Limited**

Robert Iervasi

Chair

1300 799 491

info@vitura.com.au

Media enquiries

Dieter Lehmann

Nominis Communications

+61 427 672 995

dieter@nominis.me

Forward-looking statements

This announcement includes forward-looking statements which may be identified by words such as 'anticipates', 'believes', 'expects', 'intends', 'may', 'will', 'could', or 'should' and other similar words that involve risks and uncertainties. These forward-looking statements are based on the Company's expectations and beliefs concerning future events as at the date of this announcement. Forward-looking statements are necessarily subject to risks, uncertainties, and other factors, many of which are outside the control of the Company, which could cause actual results to differ materially from such statements. The Company makes no undertaking to update or revise the forward-looking statements made in this announcement to reflect any change in circumstances or events after the date of this announcement.

About Vitura Health Limited (ASX: VIT)

- www.vitura.com.au

Vitura Health Limited is diversified digital health business listed on the ASX (ASX: VIT) and, via its subsidiaries, operates the following businesses:

- www.burleighheadscannabis.com

Burleigh Heads Cannabis operates the market leading prescriber, patient, pharmacy, and supplier online ecosystem, Canview, which sells and distributes roughly 600 therapeutic product and device SKUs within Australia from roughly 70 international and domestic brands.

- www.canview.com.au

Canview was developed to be a complete end-to-end healthcare ecosystem designed to provide doctors, pharmacists, and patients with a simple and cost-effective way to facilitate the treatment of patients with increased efficiency and compliance. The Canview system is based on a medicines wholesaling platform which seamlessly brings together several disparate SAAS (software-as-a-service) providers including inventory control, invoicing, customer management, reporting and analytics, all linked together through customised integration software owned and operated by Vitura. Underpinning the suite of SAAS elements are several bespoke, internally generated operating procedures and intellectual property assets, supported by the Canview customer support and infield customer engagement teams. Through the in-house integration of the different elements which together make up Canview, the platform provides the best user experience in the industry.

Canview provides Australian doctors with the ability to integrate their patient management systems directly with the platform and to use their patient information to generate electronic prescriptions within the Canview platform, without the need to input the patient's details. Prescriptions are then sent directly to the Canview patient app where patients can manage their treatment and submit the prescription and subsequent repeats to one of the roughly 4,700 Australian pharmacies with accounts on Canview for dispensing.

- www.doctorsondemand.com.au

The Company owns Doctors on Demand Pty Ltd, a nationwide 24/7 x 365 telehealth platform business that provide innovative primary health solutions to hundreds of thousands of B2C and B2B patients annually. Services include general medical consults, urgent care, medical certificates, pathology referrals, specialist referrals, men's health, women's health and medicated weight loss.

- www.cortexa.com.au

The Company owns 50% of Cortexa Pty Ltd, an incorporated joint venture with Canadian-based PharmAla Biotech (CSE: MDMA). Cortexa aims to be the leading supplier of psychedelics, GMP MDMA and GMP psilocybin, for research and therapeutic use in Australia.

- www.candor.com.au

The Company owns Candor Medical that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis and other speciality products and services.

- www.releaf.com.au

The Company owns a 42.5% equity interest in Flora Holdings Pty Ltd, a joint venture that owns and operates a series of medicinal cannabis clinics operating under the Releaf brand.

- www.cannadoc.com.au

The Company owns 75.5% of Cannadoc Health Pty Ltd, a medicinal cannabis clinic business that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.